The Nevoid Basal Cell Carcinoma Syndrome market growth is driven by factors like increase in the prevalence of Nevoid Basal Cell Carcinoma Syndrome, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Nevoid Basal Cell Carcinoma Syndrome market report also offers comprehensive insights into the Nevoid Basal Cell Carcinoma Syndrome market size, share, Nevoid Basal Cell Carcinoma Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Nevoid Basal Cell Carcinoma Syndrome market size growth forward.
Some of the key highlights from the Nevoid Basal Cell Carcinoma Syndrome Market Insights Report:
- Several key pharmaceutical companies, including Novartis Pharmaceuticals, DUSA Pharmaceuticals, PellePharm, Palvella Therapeutics, and others, are developing novel products to improve the Nevoid Basal Cell Carcinoma Syndrome treatment outlook.
- The total Nevoid Basal Cell Carcinoma Syndrome market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Nevoid Basal Cell Carcinoma Syndrome market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Nevoid Basal Cell Carcinoma Syndrome Market Landscape
Nevoid Basal Cell Carcinoma Syndrome Overview
Nevoid basal cell carcinoma syndrome is a rare, complex genetic disorder characterized by a wide variety of developmental abnormalities and a predisposition to developing certain forms of cancer, particularly a type of skin cancer known as basal cell carcinoma. The specific symptoms and severity of NBCCS can vary greatly from one individual to another, even among members of the same family.
Multiple organ systems can become involved. Common symptoms include multiple basal cell carcinomas, recurrent keratocystic odontogenic tumors of the jaws, pits of the palms and soles, and skeletal malformations. Some affected individuals may have distinctive facial features. The onset of specific symptoms can vary, occurring anywhere from infancy through adulthood. Most cases of NBCCS are caused by changes (mutations) in the PTCH1 gene, but mutations in the SUFU and PTCH2 genes can cause similar characteristics (phenotype).
All three genetic forms of the disorder are inherited in an autosomal dominant pattern. However, sporadic cases due to new mutations are common.
Nevoid Basal Cell Carcinoma Syndrome Causes
NBCCS is a genetic condition. This means that the cancer risk and other features of NBCCS can be passed from generation to generation in a family. The most common gene associated with NBCCS is called PTCH. A mutation (alteration) in the PTCH gene gives a person an increased risk of basal cell skin cancer and other symptoms of NBCCS. Research is ongoing to learn more about NBCCS and to identify other genes involved, such as SUFU.
Sun exposure and radiation therapy increase the number of basal cell skin cancers that a person with NBCCS develops. Some individuals may have thousands of basal cell cancers in areas of skin that are exposed to the sun or radiation therapy.
Nevoid Basal Cell Carcinoma Syndrome Diagnosis
NBCCS is diagnosed when a person has at least 2 major features of NBCCS and 1 minor feature, or 1 major feature and at least 3 minor features.
Major Features:
- Multiple (more than 2) basal cell skin cancers that appear earlier in life than is usual
- Increased calcium deposits in the head that can be seen on an x-ray
- Jaw or bone cyst(s)
- 3 or more pits on the palms of the hands or soles of the feet
- A parent, sibling, or child with NBCCS
Minor Features:
- Medulloblastoma
- Increased head size and large forehead
- Cleft lip or palate, extra fingers or toes
- Abnormal shape of the ribs or spinal bones
- Eye problems such as cataracts, small eyes, or tumors in the iris
- Fibromas, meaning benign fibrous tumors, of the ovaries or heart
- Abdominal cysts
If a person has a family history of NBCCS, that person is also suspected of having NBCCS if they have jaw cysts, multiple basal cell skin cancers, pits on the palms of the hands or soles of the feet, or calcium deposits in the head. Genetic testing for mutations in the PTCH gene is available for people suspected to have NBCCS. A mutation in the PTCH gene is found in up to 85% of people diagnosed with NBCCS.
Do you know the treatment paradigms for different countries? Download our Nevoid Basal Cell Carcinoma Syndrome Market Sample Report
Nevoid Basal Cell Carcinoma Syndrome Epidemiology Segmentation
DelveInsight’s Nevoid Basal Cell Carcinoma Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Nevoid Basal Cell Carcinoma Syndrome historical patient pools and forecasted Nevoid Basal Cell Carcinoma Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Nevoid Basal Cell Carcinoma Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Nevoid Basal Cell Carcinoma Syndrome Prevalence
- Age-Specific Nevoid Basal Cell Carcinoma Syndrome Prevalence
- Gender-Specific Nevoid Basal Cell Carcinoma Syndrome Prevalence
- Diagnosed and Treatable Cases of Nevoid Basal Cell Carcinoma Syndrome
Visit for more @ Nevoid Basal Cell Carcinoma Syndrome Epidemiological Insights
Recent Breakthroughs in the Nevoid Basal Cell Carcinoma Syndrome Market:
- Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million: Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022, announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc. Gorlin syndrome is a rare disease with no currently approved therapies by the U.S. Food and Drug Administration (FDA) or European Medical Association (EMA). Sol-Gel broadens its pipeline with this new chemical entity, designated as investigational compound SGT-610, which has the potential to be the first-ever drug for treatment of Gorlin syndrome. Sol-Gel expects the transaction to close on or about January 30, 2023, subject to the satisfaction of customary closing conditions.
Nevoid Basal Cell Carcinoma Syndrome Treatment Market
The Nevoid Basal Cell Carcinoma Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Nevoid Basal Cell Carcinoma Syndrome market trends by analyzing the impact of current Nevoid Basal Cell Carcinoma Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Nevoid Basal Cell Carcinoma Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Nevoid Basal Cell Carcinoma Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Nevoid Basal Cell Carcinoma Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Nevoid Basal Cell Carcinoma Syndrome Key Companies
- Novartis Pharmaceuticals
- DUSA Pharmaceuticals
- PellePharm
- Palvella Therapeutics
Nevoid Basal Cell Carcinoma Therapies
- LDE225
- Patidegib
- PTX-022
For more information, visit Nevoid Basal Cell Carcinoma Syndrome Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Nevoid Basal Cell Carcinoma Syndrome Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Nevoid Basal Cell Carcinoma Syndrome, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Nevoid Basal Cell Carcinoma Syndrome epidemiology in the 7MM
- Nevoid Basal Cell Carcinoma Syndrome marketed and emerging therapies
- Nevoid Basal Cell Carcinoma Syndrome companies
- Nevoid Basal Cell Carcinoma Syndrome market drivers and barriers
Key Questions Answered in the Nevoid Basal Cell Carcinoma Syndrome Market Report 2032:
- What was the Nevoid Basal Cell Carcinoma Syndrome market share distribution in 2019, and how would it appear in 2032?
- What is the total Nevoid Basal Cell Carcinoma Syndrome market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Nevoid Basal Cell Carcinoma Syndrome market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Nevoid Basal Cell Carcinoma Syndrome market projected to expand at 7MM?
Table of Contents:
1 Nevoid Basal Cell Carcinoma Syndrome Market Key Comprehensive Insights
2 Nevoid Basal Cell Carcinoma Syndrome Market Report Introduction
3 Competitive Intelligence Analysis for Nevoid Basal Cell Carcinoma Syndrome
4 Nevoid Basal Cell Carcinoma Syndrome Market Analysis Overview at a Glance
5 Executive Summary of Nevoid Basal Cell Carcinoma Syndrome
6 Nevoid Basal Cell Carcinoma Syndrome Epidemiology and Market Methodology
7 Nevoid Basal Cell Carcinoma Syndrome Epidemiology and Patient Population
8 Nevoid Basal Cell Carcinoma Syndrome Patient Journey
9 Nevoid Basal Cell Carcinoma Syndrome Treatment Algorithm, Nevoid Basal Cell Carcinoma Syndrome Current Treatment, and Medical Practices
10 Key Endpoints in Nevoid Basal Cell Carcinoma Syndrome Clinical Trials
11 Nevoid Basal Cell Carcinoma Syndrome Marketed Therapies
12 Nevoid Basal Cell Carcinoma Syndrome Emerging Therapies
13 Nevoid Basal Cell Carcinoma Syndrome: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Nevoid Basal Cell Carcinoma Syndrome
16 Nevoid Basal Cell Carcinoma Syndrome Market Key Opinion Leaders Reviews
18 Nevoid Basal Cell Carcinoma Syndrome Market Drivers
19 Nevoid Basal Cell Carcinoma Syndrome Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Nevoid Basal Cell Carcinoma Syndrome Epidemiology 2032
DelveInsight’s “Nevoid Basal Cell Carcinoma Syndrome – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Nevoid Basal Cell Carcinoma Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Nevoid Basal Cell Carcinoma Syndrome Pipeline 2023
“Nevoid Basal Cell Carcinoma Syndrome Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Nevoid Basal Cell Carcinoma Syndrome market. A detailed picture of the Nevoid Basal Cell Carcinoma Syndrome pipeline landscape is provided, which includes the disease overview and Nevoid Basal Cell Carcinoma Syndrome treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/